Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 1.25 |
| FCF Yield | -0.54% | -2.24% | -0.57% | -0.40% |
| EV / EBITDA | -145.56 | -31.27 | 14.41 | -110.86 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -11.81% | -6.25% |
| Gross Margin | 0.00% | 0.00% | 90.19% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.86 | 0.88 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 5.25% | -293.02% | -56.42% | 66.50% |
| Safety | ||||
| Net Debt / EBITDA | 5.06 | 5.63 | -3.05 | 12.87 |
| Interest Coverage | 0.00 | 0.00 | 41.30 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -3,710.00 | 0.00 |